Create Well being Ventures, which is able to deal with investing in payer- and pharma-facing early-stage digital well being firms with founders with expertise within the healthcare trade, introduced its launch after closing its first fund of $21 million.
The VC agency will spend money on startups providing B2B platforms centered on payers and pharmaceutical firms that goal to enhance affected person engagement and the affected person care journey, together with scientific trial recruitment and retention.
“We’ve heard firsthand from payers, suppliers and pharmaceutical firms that their enterprise targets are to raise the affected person expertise, facilitate higher well being outcomes and enhance entry to look after all, particularly these with well being disparities,” Emma Cartmell, cofounder and managing associate of Create Well being Ventures, stated in a press release.
“We all know that founders from the healthcare trade intimately perceive how one can meet these challenges leveraging know-how, and supporting them is essentially the most highly effective means that we are able to make investments and, in flip, positively affect the healthcare trade.”
THE LARGER TREND
Different enterprise companies which have emerged previously 12 months centered on funding digital well being firms embrace Amboy Avenue Ventures, which launched in 2023 after closing a $20 million fund to spend money on girls’s well being and sexual wellness.
Earlier this 12 months, well being tech investor and Transcarent CEO Glen Tullman launched a brand new $100 million enterprise fund known as 62 Ventures. The brand new fund will spend money on startups outdoors his current fund 7wireVentures’ strict digital well being focus.
62 Ventures will deal with training, well being and care environmental sustainability, in addition to different industries.
Final 12 months, Tullman’s 7wireVentures launched its largest fund thus far, closing a $217 million fund, bringing its property below administration to $500 million.
The agency stated one-third of the funding would go towards Sequence B and Sequence C funding that weren’t already part of the VC agency’s portfolio.
